North Brookfield Savings Bank announces the promotion of five employees.
MEAGAN BROUSSEAU has been promoted to branch manager and will be based out of the West Brookfield Branch location. She has been in banking for 19 years. She will be responsible for managing the day to day operations of the branch, overseeing the teller line, scheduling, account openings, and inputting loan applications.
JOSEPH RIBEIRO has been promoted to the role of assistant branch manager, individual retirement account specialist, and bank security officer and will be based out of the North Brookfield branch. He has been with the bank for three years. Ribeiro will be responsible for his previous duties as well as processing account openings and assisting branch management.
Songbird system may provide new treatment options for children with autism
Inactivating a gene in young songbirds that are closely linked with autism spectrum disorder (ASD) prevents the birds from forming memories necessary to accurately reproduce their fathers songs, a new study led by UT Southwestern shows.
The findings, published online today in
Science Advances, may help explain the deficits in speech and language that often accompany ASD and could eventually lead to new treatments specifically targeting this aspect of the disorder.
Study leader Todd Roberts, Ph.D., associate professor of neuroscience and a member of the Peter O Donnell Jr. Brain Institute at UT Southwestern, explains that the vocalizations that comprise a central part of human communication are relatively unique among the animal world – not just for their complexity, but in the way they re passed down from caregivers to offspring.
E-Mail
New research from the University of Iowa and University Hospitals Cleveland Medical Center demonstrates that offspring can be protected from the effects of prenatal stress by administering a neuroprotective compound during pregnancy.
Working in a mouse model, Rachel Schroeder, a student in the UI Interdisciplinary Graduate Program in Neuroscience, drew a connection between the work of her two mentors, Hanna Stevens, MD, PhD, UI associate professor of psychiatry and Ida P. Haller Chair of Child and Adolescent Psychiatry, and Andrew A. Pieper, MD, PhD, a former UI faculty member, now Morley-Mather Chair of Neuropsychiatry at Case Western Reserve University and Investigator and Director of the Neurotherapeutics Center at the Harrington Discovery Institute, University Hospitals Cleveland Medical Center.
Methamphetamine use and resulting overdose deaths are devastating families in cities and towns across the U.S. In the world of addiction treatment, many specialists say meth is their most formidable challenge. There are no accepted medications that help patients resist the intense cravings.
That starts to change today with the publication of a study through which meth users received a combination of two approved drugs, an antidepressant and naltrexone, which is prescribed for addictions to opioids and alcohol. Among the 403 study participants, nearly 14% of those who took the combo presented mostly drug-free urine samples. It’s a modest percentage but still more than five times greater than participants who received a placebo.
Posted on 553
Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity.
Serving in key leadership roles on Aviceda’s Executive Leadership Team will be:
Mohamed Genead, MD, CEO & President,
David Callanan, MD, Chief Medical Officer,
Derek Kunimoto, MD, JD, Chief Operating Officer,
Michael Tolentino, MD, Chief Technology Officer, and
Christopher Scott, PhD, Chief Scientific Officer.